More than half of patients with moderate-to-severe thyroid eye disease who do not improve with corticosteroids achieve disease control after 6 months of treatment with tocilizumab. Medscape Medical News
Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
GENEVA–(BUSINESS WIRE)–Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
GENEVA–(BUSINESS WIRE)–Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
Unexplained Pediatric Mucositis: Could It Be RIME?
Early diagnosis of reactive infectious mucocutaneous eruption is important to minimize potential long-term disease complications. Medscape Medical News
AAO 2025: AI’s Role in the Future of Retinal Disorders
Dr Sunir Garg explores how AI is transforming retinal care, from individualized treatments to tracking disease progression and bridging gaps across specialties. Medscape
Uncategorized
Aflibercept, faricimab show treatment interval extension, safety
NEW YORK — Real-world data demonstrated an extension of treatment intervals and positive safety results for aflibercept 8 mg and faricimab when used to manage retinal diseases, according to a presenter.At the OSN New York Retina meeting, Rishi P. Singh…